secwatch.observer — SEC 8-K summary
======================================

Issuer:     BRAINSTORM CELL THERAPEUTICS INC. (BCLI)
CIK:        0001137883
Form:       8-K
Filed at:   2024-09-26T23:59:59+00:00
Accession:  0001104659-24-103157
Event type: other_material
Sentiment:  negative
Materiality: 0.55
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Brainstorm Cell Therapeutics announces 1-for-15 reverse stock split effective Sept 30
--------------------------------------------------------------------------------

- Board approved 1-for-15 reverse stock split on Sept 23, 2024; stockholders authorized at Sept 16 meeting.
- Reverse split effective at 11:59 p.m. ET on Sept 30, 2024; trading on split-adjusted basis Oct 1 under BCLI.
- No fractional shares issued; cash in lieu based on closing price prior to effective time.
- New CUSIP number 10501E 300; par value unchanged at $0.00005 per share.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1137883/000110465924103157/0001104659-24-103157-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1137883/000110465924103157/tm2424656d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-103157

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer